The crossover design has a long history in the planning of scientific trials ([1], sect. 1.4) and forms the basis of a large number of clinical studies year after year.

Even though it doesn’t mean just any company with a crossover trial design can now expect to win over the FDA, Cabometyx serves as living proof that the agency is open to that line of reasoning.

Conducted as an interventional study, it employs a randomized, crossover design without masking, focusing on basic science. This approach allows each participant to receive multiple formulations, ...

In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent ...

If it were only marginally significant, then in the context of a significant IPCW analysis, the benefit of the new therapy may still be substantial. In the end, to avoid this issue, it would be best ...

In this trial, we used an open-label, multicenter, randomized, crossover design to compare the use of hybrid closed-loop insulin delivery for 16 weeks, followed by the use of sensor-augmented pump ...

(RTTNews) - Aldeyra Therapeutics, Inc. (ALDX) announced Tuesday the achievement of the primary endpoints in a sequence-randomized, double-masked, vehicle-controlled crossover clinical trial of 0. ...

CG Oncology has raised the rarely seen crossover round. Once ubiquitous, the pre-IPO rounds have dried up in the biotech bear market—but CG’s fully enrolled phase 3 bladder cancer clinical ...